SCHEMBL3629238

SCHEMBL3629238

O=C(NN=Cc1cc(Br)c(O)c(Br)c1)c1ccc(Br)c(Cl)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
LMNA P02545 1/20 0.60
MAPT P10636 1/20 0.60
SIRT1 Q96EB6 4/20 0.55
ASF1A Q9Y294 7/20 0.54
POLB P06746 2/20 0.53
CHEK1 O14757 1/20 0.51
AURKA O14965 1/20 0.51
DAPK3 O43293 1/20 0.51
JAK2 O60674 1/20 0.51
PRKD3 O94806 1/20 0.51
MAP4K4 O95819 1/20 0.51
PAK4 O96013 1/20 0.51
ABL1 P00519 1/20 0.51
NTRK1 P04629 1/20 0.51
LCK P06239 1/20 0.51
CSF1R P07333 1/20 0.51
RET P07949 1/20 0.51
IGF1R P08069 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3629235 1.00 MEN1 (0.60) MEN1KMT2ALMNAMAPTSIRT1
SCHEMBL3633321 0.90 MEN1 (0.60) MEN1KMT2ALMNAMAPTSIRT1
SCHEMBL3633326 0.90 MEN1 (0.60) MEN1KMT2ALMNAMAPTSIRT1
SCHEMBL1669542 0.86 SIRT1 (0.72) MEN1KMT2ALMNAMAPTSIRT1
SCHEMBL1669543 0.86 SIRT1 (0.72) MEN1KMT2ALMNAMAPTSIRT1
SCHEMBL1672418 0.83 KMT2A (0.69) MEN1KMT2ALMNAMAPTSIRT1
SCHEMBL1672421 0.83 KMT2A (0.69) MEN1KMT2ALMNAMAPTSIRT1
SCHEMBL1672478 0.82 MEN1 (0.60) MEN1KMT2ALMNAMAPTSIRT1
SCHEMBL1672482 0.82 MEN1 (0.60) MEN1KMT2ALMNAMAPTSIRT1
SCHEMBL1669361 0.81 SIRT1 (0.74) MEN1KMT2ALMNAMAPTSIRT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142498-A2 CFTR INHIBITOR COMPOUNDS AND USES THEREOF Institute for Oneworld Health (US) 2010-01-13 EP claimed
US-20080269206-A1 CFTR INHIBITOR COMPOUNDS AND USES THEREOF INSTITUTE FOR ONEWORLD HEALTH 2008-10-30 US claimed
WO-2008121877-A2 CFTR INHIBITOR COMPOUNDS AND USES THEREOF INSTITUTE FOR ONEWORLD HEALTH (US) 2008-10-09 WO claimed
US-8283351-B2 Inhibiting cyctic fibrosis transmembrane conductance regulator polypeptide ; therapy for diarrhea and polycystic kidney disease INSTITUTE FOR ONEWORLD HEALTH (US) 2012-10-09 US disclosed
EP-2142498-A2 CFTR INHIBITOR COMPOUNDS AND USES THEREOF Institute for Oneworld Health (US) 2010-01-13 EP disclosed
US-20080269206-A1 CFTR INHIBITOR COMPOUNDS AND USES THEREOF INSTITUTE FOR ONEWORLD HEALTH 2008-10-30 US disclosed
WO-2008121877-A2 CFTR INHIBITOR COMPOUNDS AND USES THEREOF INSTITUTE FOR ONEWORLD HEALTH (US) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269206-A1 CFTR INHIBITOR COMPOUNDS AND USES THEREOF CFTR, PKD1, PKD2 MEN1 2759/4885KMT2A 4688/4885LMNA 4314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.